Related Experiment Video
Updated: Jan 22, 2026

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy
Published on: August 25, 2019
Preimplantation genetic diagnosis (PGD) and genetic testing for aneuploidy (PGT-A): status and future challenges
Romualdo Sciorio1, Luca Tramontano2, James Catt3
1Edinburgh Assisted Conception Programme, EFREC, Royal Infirmary of Edinburgh, Edinburgh, UK.
Insights
Preimplantation genetic testing (PGT) has evolved significantly since its inception. This review clarifies preimplantation genetic diagnosis (PGD) and preimplantation genetic aneuploidy (PGT-A) and discusses current methodologies.
Area of Science:
- Reproductive Medicine
- Genetics
- Embryology
Background:
- In vitro fertilization (IVF) has resulted in over 7 million births globally since 1978.
- Preimplantation genetic diagnosis (PGD) emerged in the late 1980s for genetic abnormality screening.
- Preimplantation genetic screening (PGS), now PGT-A, evolved as an IVF embryo selection tool in the mid-1990s.
Purpose of the Study:
- To differentiate between preimplantation genetic diagnosis (PGD) and preimplantation genetic aneuploidy testing (PGT-A).
- To review current indications for embryo biopsy and genetic analysis in assisted reproductive technologies.
- To discuss the advancements in methodologies for euploid embryo selection.
Main Methods:
- Review of historical and current genetic analysis technologies used in PGT.
- Discussion of embryo biopsy techniques and their impact on genetic testing.
- Analysis of cytogenetic advancements enabling improved PGD and PGT-A.
Main Results:
- Evolution from fluorescent in situ hybridization (FISH) to advanced cytogenetic methods.
- Development of various technologies for identifying euploid embryos for transfer.
- Improved efficacy of IVF cycles through targeted embryo selection.
Conclusions:
- PGT-A aims to enhance IVF efficacy by selecting euploid embryos.
- Advancements in biopsy and genetic analysis have refined PGD and PGT-A.
- Understanding PGD vs. PGT-A is crucial for optimizing IVF outcomes.
Abstract:
The world's first in vitro fertilization (IVF) baby was born in July 1978 in the UK. Since then, more than 7 million infants have been born worldwide as a result of IVF. Preimplantation genetic diagnosis (PGD) was introduced in the late 1980s for couples at risk of transmitting a genetic abnormality to their children. From the mid-1990s, this technology has been employed as an embryo selection tool for patients undergoing IVF and has been known as preimplantation genetic screening (PGS). The aim of this practice has been to identify and select euploid embryos for transfer, in order to increase efficacy of IVF cycle, ensure higher implantation rates or at least decreased time to pregnancy. In the early days, fluorescent in situ hybridization (FISH) technology was used for genetic analysis. New advancements in both biopsy and cytogenetic have made possible the improvement of PGD and PGT-A analysis. Currently, a variety of technologies have been implemented to individuate euploid embryos to be preferentially transferred in IVF treatments. The purpose of this review is to clarify the differences between PGD and PGT-A, and to discuss current indications and requirements for embryo biopsy and genetic methodologies used.
Related Concept Videos
Genetics of Speciation
What is Population Genetics?
What is Genetic Engineering?
Animal Mitochondrial Genetics
Types of Genetic Transfer Between Organisms
Mutation, Gene Flow, and Genetic Drift

